Development and Validation of a HPLC-UV Method for Antihypertensive Drug Amlodipine in Simulated Human Plasma Application to Protein Binding Studies
Alka Singh1*, Jitendra Bajaj2
1Professor, Sagar Institute of Pharmaceutical Technology and Research, Sikandrabad,
Near Ratibad, Bhadbada Road, Bhopal, Madhya Pradesh-462044, India.
2Professor and Principal, Sagar Institute of Pharmaceutical Technology and Research, Sikandrabad,
Near Ratibad, Bhadbada Road, Bhopal, Madhya Pradesh-462044, India.
*Corresponding Author E-mail: alkasingh@sistec.ac.in
ABSTRACT:
Hypertension is persistent elevation of systolic and diastolic blood pressure to about 140/90 mm of Hg. It may be classified as “primary or essential hypertension”, where definite cause for the rise in blood pressure is not known and “Secondary hypertension”, secondary to renal, endocrine, and vascular lesions. It is well known that hypertension is major risk factor for stroke, congestive cardiac failure and coronary heart diseases. Control of hypertension reserves the risk of stroke and congestive cardiac failure.1,2
Hypertension remains the leading cause of premature death worldwide. In 2023, 1 in 5 women and 1 in 4 men had hypertension, which gives about 1.28 billion people.3 This is of particular concern because hypertension is a significant risk factor for heart, brain, kidney, and other diseases.4,5 Hypertension is also closely associated with diabetes.5 One of the most commonly used drugs for hypertension is amlodipine.6 Amlodipine is a highly effective drug used in the treatment of hypertension 7-9 21–23. However, available literature suggests that amlodipine may have additional mechanisms of action, including reduction of oxidative stress and protein glycation, which play essential roles in the pathogenesis of cardiovascular diseases.7-9
The choice of an antihypertensive drug is based on efficacy, side-effects, effects on other systems and cost. Specificity of patient’s prescription depends on individual’s age, gender, and presence of comorbid condition if any. Furthermore, the follow-up guidelines, i.e., by the World Health Organization (WHO) and the Joint National Committee (JNC) are necessary as also the follow up guidelines i.e. by World Health Organization and Joint National Committee are necessary. These guidelines are indicative as standard one and patient’s BP levels should be determined in its comparative terms. Dependency of pharmacological treatment is also on age, gender, and body mass index. In most of the cases, more than one drug is required to control BP level. The categorization of the drugs as to be given as single or in combination is dependent on JNC and other such regulations. In initial treatment terms, single therapy is being employed which later is being followed with a combined therapy on basis of patient’s health condition.10-13
Chemical class: Dihydropyridine carboxylic acids
Figure 1 Chemical Structure of Amlodipine
2-[(2-Aminoethoxy) methyl]-4-(2–chlorophenyl)-1, 4–dihydro–6–methyl–3, 5pyridine dicarboxylic acid 3–ethyl 5–methyl ester.
C20H25ClN2O5Mol. Wt.: 408.9, 525.0 (Maleate salt), 567.1 (Besylate salt)
A white crystalline powder with melting point 178° to 179°.
Amlodipine is a long-acting dihydropyridine-type (DHP) calcium channel blocker used to lower blood pressure and to treat anginal chest pain.
It is slightly soluble in water; sparingly soluble in ethanol.
LogP: 3.72, 3.0, pKa (BH+):8.6,8.73
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the movement of calcium ions into vascular smooth muscle cells and cardiac muscle cells.
Absorbed gradually over 6 to 8 hours, bioavailability is 60 to 65% under fasting condition.
Cmax:181.0 ± 7.1 ng/mL, Protein binding: ≈ 97.5%
Metabolism: Metabolized to inactive pyridine metabolite Vd:16 ± 4 (kg/L)
Toxicity: At therapeutic sub-toxic concentrations, amlodipine has little effect on cardiac myocytes and conduction cells
Usual dose range: 5mg daily to 10 mg daily maximum14
2. MATERIALS AND METHODOLOGY:
Materials which are used in the investigation are listed below:
Equipment:
Instrument: HPLC equipped with pump, injector and UV/PDA Detector
Make: Agilent 1200 series (Chromleon software)
Instrument: Analytical Balance
Make: Sartorius, Mettler Toledo
Instrument: Hot air oven
Make: Thermolab Scientific Equipments
Instrument: pH Meter
Make: Thermo and Lab India
Instrument: UV-Visible Spectrophotometer
Make: Shimadzu UV-1800 (UV-Winlab software)
FTIR spectrometer and Mass spectrometer (for characterization purpose)
HPLC Columns, drug Sample, working standard, solvents.
Material:
Amlodipine gift samples were purchased from Alkem Laboratories in Mumbai, India. The internal standard, rosiglitazone (ROSI; purity 98.85%; Fig. 1d), was obtained from relax pharmaceutical in Vadodara, India. Glycated-albumin (Gly-HSA) and recombinant human serum albumin (rHSA) qualified standards were purchased from Sigma Aldrich (Bangalore, India). A Millipore (Bangalore, India) Amicon® Ultra-centrifugal filtration device (MWCO: 10kDa) was purchased. Merck Chemical Limited (Mumbai, India) supplied analytical/ HPLCgrade salts and solvents, which were used directly without further purification.
2.1 Analytical methods for Amlodipine:
Authentication of drug samples: Drug active pharmaceutical ingredients that met the working standard were sourced from all over India. Utilising mass spectrometry, FTIR spectroscopy, and UV spectrophotometer, the active pharmaceutical ingredient was verified.
Authentication of AMLO:
UV-absorbance pattern of AMLO:
Figure
1: The wavelength maxima was found to be 239nm and specific absorbance (
) was about 340.
IR-spectral behavior of AMLO:
Figure 2: The peak assignment for AMLO
Table 1: The IR range for AMLO
|
Wavenumber (cm-1) |
Assignment |
|
Broad region from 3500-2500 |
-OH stretching in carboxylic acid |
|
3300, 3250, 3150 |
-N-H Stretching in primary and secondary amine |
|
3100 |
=C-H Stretching |
|
3040 |
Aromatic –C-H stretching |
|
2982, 2880 |
-C-H Stretching |
|
1725, 1705 |
-C=O Stretching |
|
1090 |
-C-O Stretching |
Mass-spectral behavior of AMLO:
Figure 3: Mass spectra of AMLO.
Calibration Curve of AMLO: The CC standards were prepared in the range of 5-25 μg/ml.
Figure 4: Overlain spectra of calibration curve for AMLO in MeOH: Water
Figure 5: UV spectra of calibration curve for AMLO in MeOH: Water
Table 2: Absorbance data for AMLO in MeOH: Water
|
Conc. (μg/ml) |
Absorbance |
Line equation and correlation coefficient |
||
|
Abs-1 |
Abs-2 |
Mean |
||
|
5 |
0.263 |
0.275 |
0.269 |
y = 0.0152x + 0.1916 and r2= 0.999 |
|
10 |
0.331 |
0.349 |
0.340 |
|
|
15 |
0.414 |
0.424 |
0.419 |
|
|
20 |
0.489 |
0.507 |
0.498 |
|
|
25 |
0.556 |
0.581 |
0.569 |
|
2.2 HPLC Method for Amlodipine:
Analytical Method Development of AMLO: Pre-Validation Studies: The initial RP-HPLC conditions' chromatogram had a bifurcation in peak with an unacceptable peak shape. The pH of the HPLC method was changed from 6.5 to 3.0 in the following trial. 0.2% TEA was added to the aqueous phase in addition to the pH change. A diluted AMLO standard solution (10 µg/mL) was prepared and injected into the chromatograph in the method that was ultimately optimised. The optimised method was employed in the system suitability studies.
Table 3: The system suitability studies were performed using the optimized method.
|
Stationary phase |
Thermo β-basic C18 (100x 4.6 mm i.d., 5µ) |
|
Mobile phase |
Solvent A: 10 mM Monobasic phosphate (pH 3.0) |
|
Solvent B: ACN |
|
|
Solvent ratio |
Isocratic run for 12min using ratio 35:65 of A: B |
|
λmax |
239nm |
|
Flow rate |
1.0 mL/min |
|
Injection volume |
20 µl |
|
Temperature |
Ambient (around 25° C) |
|
Sample temperature |
4 ± 2°C (prior to injection sample was stored in refrigerator) |
Table 4: System suitability studies for diluted AMLO standard solution (n=6) in the optimized RP-HPLC method
|
System suitability parameter |
USP Limit |
Results |
|
Retention time |
- |
5.1 min |
|
% RSD of Rt |
- |
0.45 |
|
Mean peak area |
- |
247421.0 |
|
% RSD of peak area |
≤ 2.0 |
0.98 |
|
Peak asymmetry factor (at 10% peak height) |
≤ 1.5 |
1.32 |
|
Capacity factor (k’) |
0.5 to 20 |
5.52 |
|
Mean Number of theoretical plates |
≥ 2000 |
2251 |
2.3 Assay method validation of AMLO:
a. Specificity of AMLO: No interference was recorded in the chromatogram of method diluent (blank) at the retention time window of diluted AMLO as shown in figure above.
Figure 6: Chromatograph of AMLO final optimized conditions
b. Linearity and Range of AMLO 10 μg/mL was chosen as the test concentration and the range for the assay method validation was 80-120% of the test concentration. As a result, concentrations of 8 to 12 μg/mL of AMLO were observed as the range for the assay method validation. A triplicate of each concentration (80, 90, 100, 110, and 120% of test concentration) was made. Chromatograms and injections into the chromatograph were both recorded.
Figure 7: 3D Overlain chromatograph of AMLO linearity solutions
c. Precision of AMLO
System precision and Method precision: The percentage RSD for the intraday condition was found to be 1.62% (less than 2.0%), demonstrating the repeatability of the proposed method.
Figure 8: The graph between peak area and concentration of AMLO reprenting its linearity.
Table 5: Peak area of AMLO Linearity solutions form 8-12 μg/ml
|
Conc. (μg/ml) |
Peak area |
Line equation and correlation coefficient |
|||
|
1 |
2 |
3 |
Mean |
||
|
8 |
201458 |
201562 |
201456 |
201492 |
y = 20844x + 36299 and r2= 0.996
|
|
9 |
221592 |
225468 |
224586 |
223882 |
|
|
10 |
245416 |
251548 |
245134 |
247366 |
|
|
11 |
270145 |
264074 |
265546 |
266588.3 |
|
|
12 |
289546 |
289987 |
273541 |
284358 |
|
Table no 6: The outcomes for the AMLO system, method, and intermediated Precision.
|
Precision |
Conc. (µg/mL) |
Peak area |
||||||
|
1 |
2 |
3 |
4 |
5 |
6 |
Mean ±SD |
||
|
System |
10 |
245875 |
245447 |
246696 |
248578 |
248956 |
244585 |
246689.5 ± 1751.5 |
|
Method |
10 |
245859 |
245587 |
250548 |
239485 |
245587 |
250054 |
246186.6 ± 3992.90 |
|
Inter-mediated |
10 |
245514 |
246325 |
239855 |
250024 |
251187 |
250248 |
247192.1 ± 4259.54 |
d. Accuracy of AMLO in HPLC
The accuracy of the method was performed by recovery studies at 80, 100 and 120% of test concentration.
Table 7: Recovery studies of AMLO in bulk
|
Concentration level |
Peak area |
% Mean recovery |
|||
|
1 |
2 |
3 |
mean |
||
|
Unfortified samples |
|||||
|
80% (8 µg/mL) |
202258 |
199854 |
203658 |
201923.33 |
99.35 |
|
100 % (10 µg/mL) |
244585 |
250224 |
260112 |
251640.33 |
98.73 |
|
120% (12 µg/mL) |
289985 |
290545 |
288985 |
289838.33 |
102.08 |
|
Fortified samples |
Mean recovery ± SD |
100.05 ± 1.45 |
|||
|
80+ 100 % (8+10 ) |
452584 |
452985 |
450214 |
451927.66 |
|
|
100+ 100 % (10+10 ) |
510025 |
499985 |
490225 |
500078.33 |
|
|
120 + 100 % (12+10 ) |
536695 |
554854 |
548578 |
546709 |
|
The % mean recovery of accuracy study was 100.05.
e. Robustness of AMLO:
Figure 9: Effect of Flow rate of pump 0.90 mL/min and 1.1 mL/min
Figure 10: Effect of change in wavelength
The desired albumin concentration (47.5 mg/mL) was achieved by dissolving approximately 475 mg of rHSA in 10 mL of 10 mM phosphate buffer (pH 7.4).
To achieve equilibrium dialysis, an 8-cell franz diffusion assembly with a dialysis chamber (MWCO 8000 D) was used. To achieve a final concentration of 10 g/mL of analyte, the chosen drug candidate stock solution was spiked to rHSA solution (containing internal standard). A pre-stabilized dialysis membrane was covered with approximately 1 ml of the resulting rHSA mixture. Phosphate buffer (pH 7.4) was placed in the receiver compartment, and the entire assembly was set to 37°. After 24 hours, the sample (1 mL) was collected and centrifuged at 5000 rpm at 5-10o for 2 minutes. After gathering the supernatant, 20 litres of sample were added to the HPLC. The samples were created in pairs, and a blank test was run. The non-specific binding (NSB) at equilibrium was calculated using following formula:
(Donor drug concentration- Receiver drug concentration)
% Non Specific= ------------------------------------------------------- x 100
(Binding Donor drug concentration at equilibrium)
Application of the validated method: To quantify protein binding of AMLO
Figure 11: Overlain UV spectrum of Amlodipine and Rosiglitazone
2.4.1 Sample preparation: Protein precipitation techniques
Figure 12: Overlain Chromatogram of blank matrix and spiked AMLO
The extraction efficiency (recovery percentage, (E%)) of amlodipine (AMLO) is calculated by comparing the analyte response (such as peak area or concentration) from an extracted sample to an unextracted standard solution representing 100% recovery.
The standard formula is:
Cextracted
E % =------------------- X 100
Cunextracted
The extraction efficiency of AMLO was about 88.52%. The Bioanalytical HPLC method was employed for quantitation of AMLO in samples obtained from ED and ultrafiltration.
Figure 13: Overlain chromatogram of % unbound AMLO with method blank as in ED and Ultrafiltration studies
In-vitro protein binding studies:
Amlodipine binds primarily to the Solow sites IIA and IIIA and probably to a lesser extent to the Solow site IB 25. As per the study in the literature, it has been documented that allosteric interactions with drug molecules such as aspirin, atenolol, quercetin, benazepril, atorvastatin, retinoic acid isomers, metalloid (arsenic-33), and others have caused AMLO to be displaced from its binding sites. An overlain chromatogram of percent unbound AMLO with method blank as in Equilibrium Dialysis (ED) and Ultrafiltration studies was shown in figure13 which was explain that percent unbound amlodipine (AMLO) compares the free drug peak from plasma ultrafiltrate or equilibrium dialysis (ED) buffer against a zero-drug method blank. The method blank shows no interfering peaks at the retention time of amlodipine (typically around 2.2 to 4.5 minutes depending on the HPLC-UV, confirming assay selectivity.
To achieve the objectives of work simple, sensitive, efficient, robust, fast and economic HPLC method was developed and validated as per Bio-analytical method validation guidelines. The developed and validated HPLC was employed to quantify drug concentration in ultrafiltrate. The extraction efficiency of amlodipine (AML) is used to optimize the recovery, purification, and chiral separation of the drug from complex matrices like pharmaceutical wastewater or biological samples. High extraction efficiency ensures accurate ultra-trace drug detection, reduces electrode surface poisoning in sensors, and maximizes the enantiomeric purity of active isomers like(S)amlodipine. In a previously published study, we had found that AMLO bind to albumin with a concentration of over 95%, whereas binding to glycated albumin (Gly -HSA) was reduced by almost 80%. As opposed to AMLO has a stronger affinity for albumin. Amlodipine reduces sugar- and aldehyde-induced protein glycation to a level comparable to aminoguanidine and NAC. The in-silico analysis demonstrated a strong affinity of amlodipine for αA, αG, and SI, which may explain antiglycation effects in vivo. In the docking between amlodipine and AGE pathway proteins, promising results were also obtained, and a systematic literature review confirmed the antioxidant effect of amlodipine. The antiglycation effect of amlodipine may be one of the mechanisms driving the pleiotropic effects of amlodipine, alongside its antioxidant, anti-inflammatory, and endothelial function-improving effects. Amlodipine could be used for more than just treating hypertension. So we can say that such types of replacement may be use for further research along with combination with other category of drugs like anti diabetics or in antihypertensive combination therapy. So that the free drug concentration will be enhanced and it will increase the potency of one drug if combination therapy will be use. The extraction efficiency of AMLO was about 88.52%. The Bioanalytical HPLC method was employed for quantitation of AMLO in samples obtained from Equilibrium Dialysis and ultrafiltration.
REFERENCES:
1. Chobanian, A. V.; Bakris, G. L.; Black, H. R.; Cushman, W. C.; Green, L. A.; Izzo, J. L., Jr.; Jones, D. W.; Materson, B. J.; Oparil, S.; Wright, J. T., Jr.; Roccella, E. J.; National Heart, L.; Blood Institute Joint National Committee on Prevention, D. E.; Treatment of High Blood, P.; National High Blood Pressure Education Program Coordinating, C. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560-72.
2. Choi, D.H.; Piao, Y.J.; Choi, E. J.; Choi, J.-S.; Burm, J.P. Effects of Amlodipine on the Pharmacokinetics of Warfarin after Oral and Intravenous Administration of Warfarin in Rats. Biomolecules and Therapeutics. 2011, 19.
3. Kario, K., Okura, A., Hoshide, S. and Mogi, M. The WHO global report 2023 on hypertension warning the emerging hypertension burden in Globe and its treatment strategy. Hypertens. Res. 2024; 47: 1099–1102.
4. Elliott, W. J. Systemic Hypertension. Curr. Probl. Cardiol. 2007; 32: 201–259.
5. Kokubo, Y. and Matsumoto, C. Hypertension is a risk factor for several types of heart disease: review of prospective studies. Adv. Exp. Med. Biol. 2017; 956: 419–426.
6. Wang, J. G., Palmer, B. F., Anderson, V., Sever, P. and K. and Amlodipine in the current management of hypertension. J. Clin. Hypertens. (Greenwich). 2023; 25: 801–807.
7. 21. Moon, J. S. and Won, K. C. Oxidative stress: link between hypertension and diabetes. Korean J. Intern. Med. 2017; 32: 439–441.
8. Kim, H. J. et al. Effects of Valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study. Korean J. Intern. Med. 2017; 32: 497–504.
9. Frampton, J. E. and Scott, L. J. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Am. J. Cardiovasc. Drugs. 2009; 9: 309–330.
10. “Section 11. Cardiovascular Disorders – Chapter 85. Hypertension”. Merck Manual of Geriatrics. July 2005. Archived from the original on 2009-01-23.
11. “Decision aid helps pregnant women with high blood pressure”. NIHR Evidence. 15 February 2023
12. “Hyperaldosteronism”. The Lecturio Medical Concept Library. Retrieved 25 July2021
13. Ahmed M; Alshabrawy A; and Nageh A. UPLC-MS/MS Method for Kinetic Studies and Simultaneous Determination of Amlodipine and Atorvastatin in Bulk, and Their Combined Dosage Form. Anal Chem Ind J. 2016; 16(14): 102.
14. Cryer, M. J., Horani, T. and DiPette, D. J. Diabetes and hypertension: A comparative review of current guidelines. J. Clin. Hypertens. (Greenwich). 2016; 18: 95–100.
15. M; Alshabrawy A; and Nageh A. UPLC-MS/MS Method for Kinetic Studies and Simultaneous Determination of Amlodipine and Atorvastatin in Bulk, and Their Combined Dosage Form. Anal Chem Ind J. 2016; 16(14): 102.
16. Karolina Dańkowska, Miłosz Nesterowicz, Kamil Klaudiusz Lauko, Daria Trocka, Małgorzata Żendzian-Piotrowska, Jerzy Robert Ładny, Anna Zalewska, Marta Żebrowska-Gamdzyk and Mateusz Maciejczyk. In vitro and in silico studies and a systematic literature review of antiglycation properties of amlodipine. Scientific Reports. 2025; 15: 33277.
|
Received on 04.07.2026 Revised on 30.07.2026 Accepted on 20.08.2026 Published on 12.09.2026 Available online from September 19, 2026 Asian J. Research Chem.2026; 19(5):435-441. DOI: 10.52711/0974-4150.2026.00064 ©A and V Publications All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License. |
|